IBS-D Gut Hormone: 40% Cases & Potential Cure

Unlocking the Mystery of Chronic Diarrhea: INSL5 Emerges as⁣ a Key Player

Cambridge, UK – A groundbreaking study led by researchers at the University⁢ of Cambridge, in collaboration with pharmaceutical company Eli Lilly, has identified a gut hormone, INSL5, as a potential key player in chronic diarrhea, especially⁣ in cases of bile acid diarrhea.This discovery, facilitated by a⁣ new antibody test capable of detecting minute‍ amounts of INSL5, offers hope for improved diagnosis and novel treatment strategies for a condition that affects millions worldwide.

For years,⁤ the precise mechanisms behind chronic‍ diarrhea have remained elusive, frequently enough leading to misdiagnosis and ineffective treatments. While conventional medical approaches focus on infections, inflammation, and food intolerances, the role of gut hormones has been largely overlooked. This new research shines a spotlight on INSL5, ⁣suggesting it could be a crucial, yet previously unacknowledged, factor in gut health.

the inquiry began with ⁤a study at the University of Adelaide, which explored ways to stimulate the release of GLP-1, a hormone central to weight-loss drugs. Researchers found that administering a bile acid enema to healthy volunteers successfully triggered GLP-1 release but, unexpectedly, also induced diarrhea. When the Cambridge team analyzed samples from this study, they observed a significant,⁤ temporary⁤ surge ⁤in INSL5 levels following the enema. Crucially, the higher the INSL5 levels, the more urgent ‍the need⁤ for bowel movements, strongly indicating INSL5S⁣ involvement in diarrhea.

Further bolstering this finding, the Cambridge team examined samples from patients with bile acid diarrhea, provided by⁢ Professor Julian Walters at Imperial College London. Their analysis revealed that INSL5 levels, which were almost undetectable in healthy individuals, were markedly elevated in patients with bile acid diarrhea. Moreover,a direct correlation was found between higher INSL5 levels and the wateriness of stool samples,reinforcing INSL5’s role in this specific type of diarrhea.

“This was ⁢a very exciting finding because it showed us that ⁢this hormone could be‍ playing a big part in symptoms of this misunderstood condition,” stated Dr. Chris Bannon, the study’s first author from⁤ the University of Cambridge. “It also meant it might allow us to develop a blood test to help diagnose bile acid diarrhea if INSL5 levels are only high in these individuals.”

The potential implications extend beyond diagnosis. INSL5 presents a promising new target for therapeutic intervention. In a subsequent phase of ⁢the research, samples from patients with irritable Bowel Syndrome (IBS) who had been treated with ondansetron, an anti-sickness medication known to block⁣ INSL5 activity in mice, were analyzed. These samples, obtained from Professor⁤ Robin Spiller at the university of Nottingham, revealed that ⁣approximately 40% of these patients exhibited elevated INSL5 levels, even after bile acid malabsorption had been ruled out. Significantly, these patients showed the⁤ most positive response⁢ to ondansetron.

While the exact mechanism by which ondansetron alleviates symptoms is still under investigation, its known side effect of constipation offers a clue. The research team plans to explore this further, aiming to repurpose ondansetron or develop more targeted treatments. Current treatments for bile acid diarrhea, such as bile acid sequestrants, are only effective in about two-thirds of patients, highlighting the need for choice solutions.

Dr.Bannon offered a compelling perspective on INSL5’s function: “I ofen get asked why we would have a hormone that gives you diarrhea. I think of it as⁣ a kind of poison sensor. bile acids aren’t meant to be in the colon – they’re an ‍irritant⁣ to the colon and they’re toxic to the microbiome. It makes sense⁤ that you would have something that detects toxins and helps the body rid itself of them. But a problem develops if it’s always being triggered by bile acid, causing very dramatic symptoms.”

This pioneering research, supported by the⁤ Medical Research Council, Wellcome, and the National Institute for Health⁣ and Care Research Cambridge Biomedical Research Centre, marks a significant step forward in understanding and treating chronic diarrhea. By identifying INSL5 as a critical mediator, scientists are paving the way for more accurate diagnoses and the development of⁤ much-needed effective treatments for a debilitating condition.